• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Public-private partnerships can accelerate the end of hepatitis C

Home > Viewpoints

Public-private partnerships can accelerate the end of hepatitis C

Man with his wife sitting on a bench
14 Jun 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Greg GarrettViewpoint by

Greg S. Garrett, Director of Business Development & Alliance Management, DNDi

Since joining DNDi in August 2020, I have been trying to understand what is preventing health systems around the world from ensuring all people living with hepatitis C have access to life-saving treatment. Hepatitis C is unique among infectious diseases: highly effective treatments that cure people completely – direct-acting antivirals – already exist. Yet a mere 13% of people with the disease have had access to the drugs.

Fifty-eight million people are living with hepatitis C, and 800 people die from the disease every day. Accelerating access to DAAs will save lives and create a pathway for halting transmission and eliminating hepatitis C altogether.

I am convinced that one of the major barriers standing between people and their access to a cure is the dearth of effective collaborations between the public and private sectors that bring testing and treatment to scale. Fortunately, we have some successful examples of public-private partnership to learn from – alliances that have delivered innovation, helped drive down costs, and improved access to treatment. We can and must replicate these.

A South-South partnership delivers

One such public-private partnership has led to the development and approval of the drug ravidasvir – an entirely new chemical entity – for use as part of a new combination treatment for hepatitis C. Granted conditional registration by the Malaysian government on 4 June, ravidasvir will be affordable and suitable for people with harder-to-treat forms of hepatitis C and people with HIV coinfection.

Ravidasvir stands out as the very first drug for hepatitis C delivered through South-South collaboration. The public-private partnership that advanced the drug from development to registration was forged five years ago by Pharco Pharmaceuticals[i], Pharmaniaga Berhad of Malaysia, the Malaysian Ministry of Health, and the non-profit R&D organization DNDi.

There is much to learn from this partnership – from the Malaysian Ministry of Health’s leadership and resolve, to middle-income country industry players’ commitment to dedicating vital know-how and resources. Notably, the partnership succeeded without the support of large pharma partners, a demonstration of the burgeoning capacity of stakeholders in low- and middle-income countries (LMICs) to deliver solutions that address priority public health needs.

The secret to success?

Let us start with the private sector and its contributions. Presidio Pharmaceuticals, the originator of ravidasvir, and Pharco Pharmaceuticals of Egypt committed up-front to a pro-access vision, including an equitable licensing scheme to enable rapid scale-up of generic manufacturing. Soon after, Pharco and Pharmaniaga Berhad committed to support the development and scale-up of the active ingredient, manufacture the tablets, complete nearly two dozen toxicology studies to demonstrate safety, and prepare the registration dossier. Pharmaniaga contributed USD 2.2 million to support the registration process.

High prices for DAAs remain a major barrier to treatment scale-up in countries that lack access to more affordable generic DAAs. Putting public health and people’s needs at the top of their agenda, these industry partners committed to affordability from the outset, and to pricing ravidasvir, a novel drug, as close as possible to the price of a generic. Partners also kept R&D expenditure much lower than costs cited for traditional drug development programmes, offering lessons on how to conduct patient-centred R&D efficiently.

Leadership from the public sector has also been critical – particularly the political courage demonstrated by the Malaysian government. Following years of negotiations, Malaysia was unable to secure a price lower than USD 12,000 per 12-week treatment from an originator pharmaceutical company. In order to launch a large-scale ‘test-and-treat’ programme with the potential to reach all people in need, Malaysia issued a government-use compulsory license that enabled it to purchase sofosbuvir, used in combination with ravidasvir, for less than USD 300 per treatment.

With an affordable treatment option in hand, Malaysia embarked on a large-scale screening programme to identify people living with hepatitis C and link patients to treatment while also co-sponsoring clinical trials to prove the safety and efficacy of ravidasvir.

For its part, true to its broker role as ‘conductor of the orchestra’, DNDi worked to bring partners together, focus R&D priorities, and support the STORM-C-1 clinical trial for ravidasvir. Trial results published in The Lancet Gastroenterology & Hepatology in April 2021 showed cure rates of 97%.

Resources and leadership to sustain progress

Moving forward, there is a clear role that governments must play – especially in middle-income countries – in allocating budget and sufficient resources for hepatitis C testing and treatment programmes. There is an onus on pharmaceutical companies to ensure appropriate and affordable pricing for DAAs. And civil society and non-profit organizations will be crucial to bringing stakeholders together in partnership.

At DNDi, we are now working to go further to foster an enabling environment for improved availability of all hepatitis C diagnostics and treatments in LMICs. Our teams are working to grow an industry coalition to help replicate the success of the ravidasvir partnership, and we aim to help broker new public-private partnerships that can design innovative financing mechanisms with countries to bring testing and treatment to scale. Prioritizing new strategic alliances with industry and government partners in LMICs, our aim is to advance the South-South cooperation needed to drive down prices and improve access to all DAAs.

Arguably, we have all the tools we need to bring an end to the hepatitis C epidemic. Delivering them is the challenge, and that requires harnessing public leadership and private sector initiative – for the millions of people still waiting for a cure.


[i] Pharco is a leading pharmaceutical company in Egypt, with a market share of 13%. It produces 500 different generic and over the counter drugs, as well as Hepatitis C treatments including ravidasvir. The Pharco Group is composed of five pharma and two trading companies.

Photo credit: Abang Amirrul Hadi – DNDi

Partnership Hepatitis C Africa Asia Egypt Malaysia

Read, watch, share

Loading...
Doctor with patient
News
5 Jun 2023

Marking DNDi’s 20th year of driving medical innovation for the most neglected

Mother and child smiling
News
1 Jun 2023

Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation

Statements
24 May 2023

DNDi interventions at the 76th World Health Assembly

Statements
19 May 2023

DNDi’s briefing note for 76th World Health Assembly

Viewpoints
14 Apr 2023

Bringing Chagas disease care closer to people who need it

Mother standing in front of her adolescent son
Stories
13 Apr 2023

Diagnosis & treatment closer to patients

Woman holding pills in her hand
Press releases
12 Apr 2023

Publication demonstrates how equitable deals for access to medicines can be signed with pharmaceutical industry

Researchers in lab environment
Press releases
7 Apr 2023

eWHORM project launched to eliminate worm infections in Sub Saharan Africa

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo